Navigation Links
D-Pharm Submits Investigational New Drug Application and Special Protocol Assessment to the FDA for Phase III Trial of DP-b99 in Acute Stroke Patients
Date:5/6/2009

l protocol for a trial from which the data will form the primary basis for a claim of efficacy. In general, the SPA can significantly reduce development time since the design of the pivotal protocol has been approved in advance.

About DP-b99

DP-b99 is a unique neuroprotective drug that addresses an array of brain damaging processes occurring in stroke patients and emerged from D-Pharm's proprietary Membrane Activated Chelator (MAC) platform technology. D-Pharm successfully completed extensive testing of DP-b99 in pre-clinical and then in Phase I and Phase II clinical studies. Both preclinical and clinical studies indicate a favorable efficacy and safety profile for DP-b99. In the recently completed Phase IIb trial in 150 ischemic stroke patients, DP-b99 increased by two-fold the percentage of patients that completely recovered from ischemic stroke. DP-b99 may be administered within a nine hour therapeutic window.

About Stroke

Every year approximately 780,000 Americans have a new or recurrent stroke. The second most common cause of death worldwide, stroke is also the leading cause of serious long-term disability; 15% to 30% of stroke survivors experience permanent disability. According to the American Heart Association, the estimated direct and indirect cost in 2009 of stroke in the US is $68.9 billion. Other than tissue plasminogen activator (tPA), which must be administered 3 hours after stroke, there are no FDA approved medicines for this indication.

About D-Pharm Ltd.

D-Pharm (http://www.dpharm.com) is a clinical stage, biopharmaceutical company pioneering the development of lipid-like therapeutics and has generated a rich pipeline of patent protected proprietary products. D-Pharm's pipeline includes advanced clinical stage products DP-b99 for treatment of acute ischemic stroke patients and DP-VPA, a novel dr
'/>"/>

SOURCE D-Pharm Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AstraZeneca Submits NDA for Low Dose Aspirin/Esomeprazole Combination Product
2. U.S. Naval Medical Research Center Resubmits IND Application for Proposed RESUS Clinical Trial in Trauma Patients in the Out-of-Hospital Setting
3. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
4. Isolagen, Inc. Submits Biologics License Application for the Treatment of Wrinkles to the U.S. Food and Drug Administration
5. Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents
6. ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410
7. Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children
8. U.S. Naval Medical Research Center Resubmits IND Application for Proposed Op RESUS Clinical Trial in Trauma Patients in the Battlefield Setting
9. Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
10. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
11. U.S. Navy Submits Protocol for Field Trauma Trial of Hemopure(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 25, 2014 Research and Markets ... Diagnostic Devices Market 2014-2018" report to their offering. ... About Ophthalmic Diagnostic Device An ophthalmic ... a defect or deficiency in the human visual pathway. ... such as presbyopia, cataracts, glaucoma, retinal disorders, conjunctivitis, and ...
(Date:7/25/2014)... Ore. , July 25, 2014  Semler ... an emerging medical risk assessment company that develops ... patients and evaluating chronic diseases, today reported financial ... ended June 30, 2014. "The ... for Semler," said Doug Murphy-Chutorian , M.D., ...
(Date:7/25/2014)... , July 25, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... a corporate update and report second quarter 2014 financial ... Friday, August 1, 2014. That same day, Arena will ... Eastern Time (5:30 a.m. Pacific Time). ... for domestic callers and 914.495.8552 for international callers. Please ...
Breaking Medicine Technology:Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2Semler Reports Second Quarter 2014 Financial Results 2Semler Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3
... Children,s DNA, a Hint of a Mutation,s Ancestral African ... to replicate another group,s discovery of an important gene,associated ... particular,variant in DNA that may be more helpful in ... worldwide. The finding suggests that,the gene variant, identified in ...
... daily,"Profile America" feature from the U.S. Census Bureau:, ... -- Tuesday, March 11th. One of the most devastating,public ... this day 90 years ago,and experts are still studying ... first cases were reported among soldiers at Fort Riley,Kansas, ...
Cached Medicine Technology:Gene Hunters Fine-Tune Marker for Common Obesity Gene 2Gene Hunters Fine-Tune Marker for Common Obesity Gene 3
(Date:7/26/2014)... As reported by Lauren Hunter of ... 3 factors: smaller spaces, multi-generational access, and water consumption. ... 2014 lists, including this article on Freshome , ... a leading manufacturer of steam bath generators, has noticed ... smaller spaces and an effort to reduce water consumption. ...
(Date:7/26/2014)... 26, 2014 As reported in ... 23rd, new research by Palo Alto Networks shows that ... playbook, now focusing more on businesses and their digital ... become increasingly wise to their tactics over the years. ... Joe Caruso, talks about the evolution of 419 scams ...
(Date:7/26/2014)... “Healthy teeth are important, and having your teeth cleaned regularly ... Health Center of Snohomish County (CHC) in their article, “ ... integration of medical and dental care is the best way ... encourage regular cleanings and checkups not only with a family ... adults will find knowledgeable and friendly staff that ...
(Date:7/26/2014)... July 26, 2014 Multiple sclerosis ... disseminata, is an inflammatory disease in which the ... and spinal cord are damaged. This damage disrupts ... to communicate, resulting in a wide range of ... psychiatric problems. Multiple sclerosis takes several forms, with ...
(Date:7/26/2014)... (PRWEB) July 26, 2014 The U.S. Food ... list that includes a new medication guide for AndroGel to ... serious side-effect of taking the topical low testosterone medication, notes ... AbbVie Inc., the makers of the low testosterone theapy drug, ... of pain, swelling or redness as signs of a blood ...
Breaking Medicine News(10 mins):Health News:Amerec Finds Bathroom Design Trends Change Based on Water Consumption and Other Factors 2Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 2Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 3Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 4Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 5Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 6Health News:Common Dental Care Questions Answered by Community Health Center of Snohomish County in Recent Article 2Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 2Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 3Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 4Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 2Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 3Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 4Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 5
... A residential summer weight-loss camp markedly improved obese ... Pediatrics reports. A Saint Louis University ... index (BMI), physical fitness and blood pressure. "Weight ... the social environment to be successful," said Nadim Kanafani, ...
... diabetes may be related to trend toward less sleep, ... Adding to the many reasons why people should get adequate ... cause insulin resistance, a component of type 2 diabetes. , ... measured after a night of normal sleep (about eight hours) ...
... levels increased more than 50% after timing change, researchers say ... make better use of a vitamin D supplement if you ... Researchers at the Cleveland Clinic examined 17 patients with vitamin ... period of two to three months, the patients were told ...
... May 2010 -- An international team of researchers has ... with HER2 over-expressing breast cancer do not respond to ... research, presented at the IMPAKT Breast Cancer Conference in ... clinical trial design and treatment strategies in HER2 over-expressing ...
... to 10 million women take hormone therapies, which are ... hormones lost from inactive ovaries. Progestin is a hormone ... of estrogen therapy on the uterus. In studies sponsored ... found that estrogen and progestin in hormone therapies increase ...
... ... held liable of confirmation fraud if an employee responds falsely to a confirmation request. ... requests, new guidance from the standards-setting boards supporting the use of secure electronic confirmations now ... ...
Cached Medicine News:Health News:The biggest winners: Summer campers 2Health News:One Sleepless Night Ups Insulin Resistance 2Health News:Estrogen receptor status of HER2+ breast cancer correlates with response to anti-HER therapies 2Health News:Breast cancer metastasis increases after estrogen and progestin hormone therapies, MU study finds 2Health News:Brian Fox to Speak on Audit Confirmation Fraud at the 2010 IAPP Annual Forum and Expo 2
...
...
...
Bimanual I&A Cannulas. Curved 45 with a .51mm open-end irrigation port. Facilitates removal of cortical debris between 10-2 o'clock. .80mm x 17.0mm...
Medicine Products: